Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

• Published in: Clinical cancer research Vol. 19; no. 8; pp. 1933 - 1940
• Main Authors: Quintás-Cardama, Alfonso, Verstovsek, Srdan
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.04.2013
• Subjects: Antineoplastic agents; Biological and medical sciences; Chemotherapy; Drug Resistance, Neoplasm - genetics; Humans; Janus Kinase 1 - antagonists & inhibitors; Janus Kinase 1 - genetics; Janus Kinase 1 - metabolism; Janus Kinase 2 - antagonists & inhibitors; Janus Kinase 2 - genetics; Janus Kinase 2 - metabolism; Medical sciences; Models, Biological; Mutation; Myeloproliferative Disorders - drug therapy; Myeloproliferative Disorders - genetics; Myeloproliferative Disorders - metabolism; Pharmacology. Drug treatments; Pyrazoles - therapeutic use; Signal Transduction - drug effects; Signal Transduction - genetics; Signal Transduction - physiology; STAT5 Transcription Factor - metabolism; Antineoplastic agent; Human; Jak protein tyrosine kinase; Treatment resistance; Myelofibrosis; Tyrosine kinase inhibitor; Hemopathy; Review; Myeloproliferative syndrome; Signal transduction; Ruxolitinib; Clinical trial; Genetics; Transduction factor STAT; Mutation; Janus kinase inhibitor

Aberrant activation of the JAK/STAT pathway has been reported in a variety of disease states, including inflammatory conditions, hematologic malignancies, and solid tumors. For instance, a large proportion of patients with myeloproliferative neoplasms (MPN) carry the acquired gain-of-function JAK2 V...